MedTrace Logo

Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate

NCT05590793 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 195

Last updated 2025-09-09

Study results available
· View outcomes & findings →

Summary

The main aim of this study is to assess the effectiveness and safety of the 6-month formulation of triptorelin pamoate in Chinese participants with locally advanced or metastatic cancer of the prostate. Participants will receive 1 injection of triptorelin pamoate 6-month formulation.

Conditions

Interventions

DRUG

Triptorelin pamoate (embonate) salt

Triptorelin pamoate 22.5 mg (6-month formulation), i.m. injection, single dose on Day 1.

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical, Director · Ipsen

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-17
Primary Completion
2024-08-20
Completion
2024-08-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05590793 on ClinicalTrials.gov